Press Releases

06.16.2017

Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

06.14.2017

Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

06.13.2017

Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey

06.13.2017

Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

06.10.2017

Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

06.09.2017

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

06.07.2017

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

06.07.2017

Sangamo Therapeutics And Pfizer Announce That Sb-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

06.06.2017

Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy

06.04.2017

Spark Therapeutics Presents Updated Preliminary Data From Hemophilia B Phase 1/2 Trial Suggesting Consistent And Sustained Levels Of Factor IX Activity At The Hemostasis And Thrombosis Research Society (HTRS) 2017 Scientific Symposium

06.03.2017

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer

05.31.2017

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery